Skip to main content

Home/ Groups/ WSU Virology
Rss Feed
Sort By: Most Recent | Popular Filter: All | Bookmarks | Topics Simple Middle
Casey Finnerty

A Bad Flu Season Hits the Halfway Mark, C.D.C. Says - NYTimes.com - 0 views

www.nytimes.com/...the-halfway-mark-cdc-says.html

influenza

shared by Casey Finnerty on 13 Jan 15 - No Cached
  • He said doctors did not recommend the antivirals often enough, and should prescribe them even before an office visit for patients with flu symptoms and a high risk of complications.
Casey Finnerty

We Now Have the Cure for Hepatitis C, but Can We Afford It? - Scientific American - 13 views

www.scientificamerican.com/...patitis-c-but-can-we-afford-it

hepatitis medicine antiviral HCV

shared by Casey Finnerty on 09 Dec 14 - No Cached
  • Later this year the U.S. Food and Drug Administration is expected to approve a new pill that can cure hepatitis C
  • It will contain two drugs, one of which is already available at $1,000 per dose, or $84,000 for a complete 12-week course. The dual-drug combination will likely cost even more
  • They also determined that the virus's genes mutate very fast—a process that has generated several equally successful varieties, called genotypes, and rendered an effective vaccine impossible to create so far.
  • ...7 more annotations...
  • its genetic material, which is made up of RNA
  • After several false starts, researchers at Vertex Pharmaceuticals, in collaboration with others, developed a protease inhibitor known as telaprevir, while scientists at Schering-Plough (which merged with Merck in 2009), created one called boceprevir.
  • The medications had harsh side effects and worked only for those patients with a particular genetic variant of the virus known as genotype 1
  • What scientists had learned from their earlier research, however, was that inactivating an enzyme or protein was not enough. To stop hepatitis C, any effective drug also had to incorporate itself into the virus's genetic code, where it would need to halt the virus's ability to make new copies of its genes and thus to make new virus.
  • Michael Sofia, then at Pharmasset, solved the problems by adding two compounds known as esters to the analogue.
  • During sofosbuvir's development, they had studied other drugs that inhibited different viral proteins and that might eliminate the need for continued use of interferon and ribavirin.
  • It is this combination, mixed in a single daily pill, that industry watchers expect the FDA to approve by October 2014. It heralds a new era of curative treatment for patients with hepatitis C. Similar drugs that work equally well for all genotypes are now in the final stages of clinical development.
« First ‹ Previous 181 - 200 of 803 Next › Last »
Showing 20▼ items per page